Eli Lilly to supply API for insulin at reduced price to IABL

Eli Lilly will supply its active pharmaceutical ingredient, or API, for human insulin at a reduced price to International Agencies, or IABL, in an effort to increase patient access and improve affordability for high-quality insulin for nearly one million people living with diabetes in Bangladesh by 2030. IABL will formulate, fill and finish human insulin vials and cartridges under its own trademark and brand name by 2025. The IABL-produced insulin will be exclusively for the Bangladesh market.